Abstract
The dried stem bark of Berberis vernae C.K.Schneid., known as "Xiao-bo-pi" in traditional Tibetan medicine, is a recognized anti-diabetic herb. This study integrates $^1$H NMR-based metabolomics, biochemical assays, molecular docking, and network analysis to evaluate its efficacy in type 2 diabetic (T2DM) rats. Results indicate that B. vernae extract significantly improves glycemic control, insulin sensitivity, and inflammatory markers. Metabolomic analysis identified 28 endogenous metabolites, 9 of which were significantly reversed by the treatment. Molecular docking highlighted ferulic acid 4-O-β-D-glucopyranoside, bufotenidine, jatrorrhizine, and berberine as key active components.
Introduction
Type 2 Diabetes Mellitus (T2DM) is a global health crisis characterized by insulin resistance and chronic systemic inflammation. Traditional Tibetan medicine has long utilized Berberis vernae for treating "wasting-thirst" diseases, yet the specific molecular mechanisms and active constituents have remained largely uncharacterized. This research aims to bridge the gap between traditional knowledge and modern pharmacology using a systems biology approach, identifying how this herb modulates complex metabolic and signaling networks.
Methodology
The study employed a multi-disciplinary workflow to decode the herb's effects:
- Animal Model Induction: Sprague-Dawley rats were fed a high-fat diet and administered Streptozotocin (STZ) to induce T2DM.
- Metabolomic Profiling: Proton Nuclear Magnetic Resonance ($^1$H NMR) was used to capture a holistic snapshot of serum metabolites. This non-targeted approach allows for the observation of systemic metabolic shifts.
- Chemical Characterization: High-Performance Liquid Chromatography (HPLC) quantified the primary constituents of the B. vernae extract, including magnoflorine and bufotenidine.
- Network Pharmacology: Researchers utilized molecular docking (Maestro) and network analysis (Cytoscape) to simulate interactions between the herb's compounds and 44 disease-related proteins, constructing a Compound-Protein-Metabolite-Disease (CPMD) network.
Results and Discussion
Metabolic Reversal and Systemic Impact
The $^1$H NMR analysis identified 28 endogenous metabolites. Multivariate statistical analysis, including PCA and OPLS-DA, demonstrated a clear separation between the normal, diabetic model, and treated groups, indicating a significant shift in the metabolic profile following disease induction and subsequent herbal treatment.
Treatment with B. vernae significantly reversed the levels of 9 key metabolites, including glucose, betaine, and various lipids. Biochemically, the extract reduced fasting blood glucose (FBG) from ~21.70 mmol/L to ~17.91 mmol/L and significantly lowered pro-inflammatory cytokines such as TNF-α (from ~299 pg/mL to ~189 pg/mL), IL-1β, and IL-6.
Identification of Active Components
Molecular docking revealed that four compounds—ferulic acid 4-O-β-D-glucopyranoside, bufotenidine, jatrorrhizine, and berberine—exhibited high affinity for T2DM-related protein targets. Notably, ferulic acid 4-O-β-D-glucopyranoside showed a 100% hit rate across all 44 target proteins, suggesting it is a primary driver of the herb's therapeutic efficacy.
Pathway Analysis
The anti-diabetic mechanisms appear linked to the regulation of the adipocytokine signaling pathway and butanoate metabolism. These findings suggest that B. vernae works by improving lipid signaling and energy homeostasis while simultaneously dampening the systemic inflammation that drives insulin resistance.
Conclusion
This study provides a comprehensive scientific basis for the traditional use of Berberis vernae in treating T2DM. By integrating metabolomics with computational docking, the researchers identified specific active compounds and metabolic pathways targeted by the herb. While these results are promising, further in vitro and clinical studies are necessary to validate the activity of individual compounds and ensure safety and efficacy in human populations.
Summary updated